{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T05:16:44Z","timestamp":1770268604066,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.ejim.2008.11.012","type":"journal-article","created":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T04:39:02Z","timestamp":1230698342000},"page":"387-393","source":"Crossref","is-referenced-by-count":23,"title":["Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists"],"prefix":"10.1016","volume":"20","author":[{"given":"Marleen","family":"Kars","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes W.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes A.","family":"Romijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2008.11.012_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","article-title":"The epidemiology of prolactinomas","volume":"8","author":"Ciccarelli","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib2","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib3","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1056\/NEJMcp025334","article-title":"Clinical practice. Prolactinoma","volume":"349","author":"Schlechte","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2008.11.012_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0889-8529(05)70124-9","article-title":"Pituitary incidentalomas","volume":"29","author":"Aron","year":"2000","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.ejim.2008.11.012_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2008.11.012_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib7","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejim.2008.11.012_bib8","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","article-title":"Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients","volume":"84","author":"Verhelst","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1023\/A:1022375429083","article-title":"Medical management of prolactin-secreting pituitary adenomas","volume":"5","author":"Molitch","year":"2002","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib10","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11102-005-5086-1","article-title":"Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists","volume":"8","author":"Hamilton","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib12","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1210\/jcem.87.7.8645","article-title":"Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome","volume":"87","author":"Losa","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib13","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1530\/acta.0.1260489","article-title":"Cabergoline in the long-term therapy of hyperprolactinemic disorders","volume":"126","author":"Ferrari","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"10.1016\/j.ejim.2008.11.012_bib14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/BF03343573","article-title":"Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma","volume":"22","author":"Cannavo","year":"1999","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ejim.2008.11.012_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","article-title":"The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas","volume":"53","author":"Di Sarno","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib16","doi-asserted-by":"crossref","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","article-title":"Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal","volume":"87","author":"Passos","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib17","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa022657","article-title":"Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia","volume":"349","author":"Colao","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2008.11.012_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","article-title":"Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men","volume":"8","author":"Chattopadhyay","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib19","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1365-2265.2005.02364.x","article-title":"Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up","volume":"63","author":"Berinder","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib20","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3171\/jns.2006.104.1.54","article-title":"Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up","volume":"104","author":"Wu","year":"2006","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejim.2008.11.012_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/eje.1.02268","article-title":"Malignant prolactinoma: case report and review of the literature","volume":"155","author":"Kars","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2008.11.012_bib22","first-page":"2247","article-title":"Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients","volume":"85","author":"Colao","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib23","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib24","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","article-title":"Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis","volume":"89","author":"Colao","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib25","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1210\/jcem-60-4-698","article-title":"Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study","volume":"60","author":"Molitch","year":"1985","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1017\/S0317167100030079","article-title":"Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension","volume":"17","author":"Van 't Verlaat","year":"1990","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.ejim.2008.11.012_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size","volume":"34","author":"Van 't Verlaat","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib28","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia","volume":"32","author":"Homburg","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1023\/A:1012884214668","article-title":"Quinagolide in the management of prolactinoma","volume":"3","author":"Schultz","year":"2000","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib30","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males","volume":"135","author":"Colao","year":"1996","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ejim.2008.11.012_bib31","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1210\/jcem-72-5-1136","article-title":"The efficacy and tolerability of CV 205-502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine","volume":"72","author":"Van der Lely","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib32","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7326\/0003-4819-112-9-668","article-title":"Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502","volume":"112","author":"Vance","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ejim.2008.11.012_bib33","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2265.1990.tb03900.x","article-title":"Treatment of macroprolactinomas with a new non-ergot, long-acting dopaminergic drug, CV 205-502","volume":"33","author":"Van 't Verlaat","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib34","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","article-title":"Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy","volume":"86","author":"Di Sarno","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib35","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment","volume":"82","author":"Colao","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"10.1016\/j.ejim.2008.11.012_bib37","doi-asserted-by":"crossref","first-page":"4596","DOI":"10.1210\/jcem.85.12.7042","article-title":"Ten-year follow-up results of transsphenoidal microsurgery in acromegaly","volume":"85","author":"Biermasz","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib38","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1210\/jc.2003-030751","article-title":"Long-term predictive value of postsurgical cortisol concentrations for cure and risk of recurrence in Cushing's disease","volume":"88","author":"Pereira","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1023\/B:NEON.0000041887.51906.b7","article-title":"Stereotactic radiosurgery for pituitary adenomas: a review of the literature","volume":"69","author":"Laws","year":"2004","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejim.2008.11.012_bib40","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/j.1365-2265.2006.02506.x","article-title":"Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas","volume":"64","author":"Minniti","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ejim.2008.11.012_bib41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-8140(96)91807-1","article-title":"Role of radiation therapy in clinical hormonally-active pituitary adenomas","volume":"41","author":"Tsang","year":"1996","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ejim.2008.11.012_bib42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00066-002-0826-x","article-title":"Radiation therapy in the multimodal treatment approach of pituitary adenoma","volume":"178","author":"Becker","year":"2002","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ejim.2008.11.012_bib43","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","article-title":"Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8\u00a0years of dopamine agonist therapy for prolactinoma","volume":"93","author":"Kars","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejim.2008.11.012_bib44","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-08-0611","article-title":"Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required","volume":"159","author":"Kars","year":"2008","journal-title":"Eur J Endocrinol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362050800318X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362050800318X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,16]],"date-time":"2019-05-16T18:08:16Z","timestamp":1558030096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362050800318X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S095362050800318X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2008.11.012","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}